XmAb5485 

XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells^[1].

TNFRSF5/CD40

XmAb5485 shows potent antibody-dependent cellular phagocytosis (ADCP) and in Ramos cells^[1].

XmAb5485 inhibits proliferation and induces apoptosis by antibody-dependent cell-mediated cytotoxicity (ADCC) in multiple primary patient-derived CLL, MCL, and plasma cell leukemia cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

XmAb5485 (6 mg/kg) cures 80% of mice of detectable tumors and displayed significant anti-tumor activity in an established large (210-350 mm³) sc Ramos tumor xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

958  [NCBI]

P25942

TNFRSF5/CD40

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eugene A. Zhukovsky, et al. An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma, Blood, Volume 112, Issue 11, 2008, Page 881.